Experimental cancer therapy trial halted early – what we know
NCT ID NCT05977322
First seen Nov 05, 2025 · Last updated Apr 28, 2026 · Updated 23 times
Summary
This early-stage study tested a new radioactive drug called 177Lu-FF58 in 24 people with advanced pancreatic, stomach, or brain cancers that had spread or couldn't be removed. The goal was to see if the drug was safe and to find the right dose. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Nijmegen, 6500HB, Netherlands
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Catalonia, 08907, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Geneva, CH 1211, Switzerland
Conditions
Explore the condition pages connected to this study.